Establish a whole-process comprehensive surveillance management mode for immune checkpoint inhibitor pneumonitis / 中华预防医学杂志
Chinese Journal of Preventive Medicine
; (12): 1176-1180, 2023.
Article
Dans Zh
| WPRIM
| ID: wpr-1045852
Responsable en Bibliothèque :
WPRO
ABSTRACT
The application of immune checkpoint inhibitors (ICIs) has shown impressive anti-tumor efficacy across multiple malignant tumors, leading to the prolonged survival period of tumor patients. However, immune-related adverse events should not be ignored. Checkpoint inhibitor pneumonitis (CIP) is a pulmonary adverse event that can occur in malignant tumor patients after receiving ICIs treatment. The incidence of CIP has been reported to range from 2.7% to 20.0% in clinical trials and real-world research. Furthermore, some patients might suffer from serious or fatal CIP, and the prognosis of such patients will be poor. Early detection, diagnosis and treatment may improve the prognosis of these patients. The establishment of a whole-process CIP comprehensive surveillance management mode covering the health care system and patients during ICIs treatment might be helpful to improve the early diagnosis and treatment capacity of CIP, which is a key measure to improve the prognosis of these patients.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Pneumopathie infectieuse
/
Inhibiteurs de points de contrôle immunitaires
/
Tumeurs du poumon
Limites du sujet:
Humans
langue:
Zh
Texte intégral:
Chinese Journal of Preventive Medicine
Année:
2023
Type:
Article